Helix Biopharma Corp.
HBPCF
$1.73
$1.13188.97%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 49.31% | 45.19% | -51.20% | -70.26% | -55.31% |
| Total Depreciation and Amortization | -45.10% | -30.39% | -21.82% | -8.74% | -0.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.46% | -99.34% | 623.67% | 601.33% | 495.60% |
| Change in Net Operating Assets | -80.90% | 176.66% | 708.08% | 321.60% | 392.04% |
| Cash from Operations | 4.06% | 28.85% | 36.90% | 43.66% | 29.88% |
| Capital Expenditure | 6.67% | 86.41% | 69.79% | 69.79% | 87.29% |
| Sale of Property, Plant, and Equipment | 30.51% | -- | 267.57% | 267.57% | 59.46% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 43.18% | 218.45% | 284.48% | 284.48% | 155.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 57.94% | -49.16% | -28.91% | 46.91% | -24.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 52.67% | -51.37% | -30.69% | 45.58% | -12.67% |
| Foreign Exchange rate Adjustments | -- | -- | 350.68% | 85.07% | -130.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.38% | -492.21% | 97.66% | 166.03% | 48.95% |